Molecular mechanisms of secondary hyperparathyroidism

被引:32
|
作者
Silver, J
Kilav, R
Sela-Brown, A
Naveh-Many, T
机构
[1] Hadassah Univ Hosp, Serv Nephrol, Minerva Ctr Calcium & Bone Metab, IL-91120 Jerusalem, Israel
[2] Hebrew Univ Jerusalem, Hadassah Med Sch, IL-91120 Jerusalem, Israel
关键词
parathyroid hormone; chronic renal failure; secondary hyperparathyroidism; renal osteodystrophy; vitamin D; phosphate;
D O I
10.1007/s004670000355
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Secondary hyperparathyroidism is a frequent complication of chronic renal failure (CRF) and a major factor in the pathogenesis of renal osteodystrophy. A high serum phosphate, decreased levels of serum 1,25(OH)(2)D-3 and the subsequently low serum calcium are the major metabolic abnormalities in CRF, which lead to the secondary hyperparathyroidism. At the level of parathyroid hormone (PTH) secretion there is insensitivity to the ambient serum calcium. PTH mRNA levels are increased by a post-transcriptional mechanism that involves the binding of PT cytosolic proteins to the PTH mRNA 3'-untranslated region (UTR). In a dietary model of secondary hyperparathyroidism due to hypocalcemia there is increased binding of parathyroid proteins to the 3'-UTR and decreased degradation as determined by an in vitro degradation assay. Changes in serum phosphate also dramatically regulate PTH mRNA stability. There is also regulation at the level of PT cell proliferation. PT cell proliferation is increased by experimental hypocalcemia or hyperphosphatemia and decreased by hypophosphatemia and administered 1,25(OH)(2)D-3. The understanding of the molecular mechanisms involved in the genesis of secondary hyperparathyroidism will allow the design of new effective strategies in the management of this troubling condition.
引用
收藏
页码:626 / 628
页数:3
相关论文
共 50 条
  • [1] Molecular mechanisms of secondary hyperparathyroidism
    J. Silver
    R. Kilav
    A. Sela-Brown
    T. Naveh-Many
    Pediatric Nephrology, 2000, 14 : 626 - 628
  • [2] Cellular and molecular mechanisms of secondary hyperparathyroidism
    Silver, J
    Levi, R
    CLINICAL NEPHROLOGY, 2005, 63 (02) : 119 - 126
  • [3] Mechanisms of secondary hyperparathyroidism
    Silver, J
    Kilav, R
    Naveh-Many, T
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2002, 283 (03) : F367 - F376
  • [4] An examination of multiple explanations for secondary hyperparathyroidism
    Phelps, Kenneth R.
    Mason, Darius L.
    CLINICAL NEPHROLOGY, 2020, 94 (02) : 70 - 77
  • [5] Use of sevelamer to examine the role of intraluminal phosphate in the pathogenesis of secondary hyperparathyroidism
    Phelps, Kenneth R.
    Stote, Kim S.
    Mason, Darius
    CLINICAL NEPHROLOGY, 2014, 82 (03) : 191 - 201
  • [6] THE MOLECULAR-BASIS OF SECONDARY HYPERPARATHYROIDISM IN CHRONIC-RENAL-FAILURE
    RAHAMIMOV, R
    SILVER, J
    ISRAEL JOURNAL OF MEDICAL SCIENCES, 1994, 30 (01): : 26 - 31
  • [7] Renal osteodystrophy and secondary hyperparathyroidism
    Fukagawa, M
    Kazama, JJ
    Kurokawa, K
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2002, 17 : 2 - 5
  • [8] Secondary Hyperparathyroidism in Heart Failure
    Morsy, Mohamed S.
    Dishmon, Dwight A.
    Garg, Nadish
    Weber, Karl T.
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2017, 354 (04) : 335 - 338
  • [9] Advances in pharmacotherapy for secondary hyperparathyroidism
    Rodriguez, Mariano
    Rodriguez-Ortiz, Maria E.
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (11) : 1703 - 1716
  • [10] Vitamin D analogues for secondary hyperparathyroidism
    Brown, AJ
    Dusso, AS
    Slatopolsky, E
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2002, 17 : 10 - 19